[Form 4] CorMedix Inc. Insider Trading Activity
Alan W. Dunton, a director of CorMedix Inc. (CRMD), reported same-day transactions on 09/12/2025 in the company's common stock and related options. He exercised a stock option with a $3.55 exercise price to acquire 10,000 shares, increasing his direct holdings to 50,250 shares, and sold 10,000 shares the same day in multiple trades at a weighted average price of $13.13, reducing his direct holdings to 40,250 shares. The Form 4 discloses the option grant date of 03/05/2024 and that those options vest monthly with full vesting one year after grant. The filing is signed and dated 09/16/2025.
Alan W. Dunton, direttore di CorMedix Inc. (CRMD), ha riportato operazioni nello stesso giorno il 12/09/2025 sulle azioni ordinarie della società e relative opzioni. Ha esercitato un'opzione con prezzo di esercizio di $3,55 per acquistare 10.000 azioni, aumentando le sue partecipazioni dirette a 50.250 azioni, e ha venduto 10.000 azioni nello stesso giorno in più operazioni a un prezzo medio ponderato di $13,13, riducendo le partecipazioni dirette a 40.250 azioni. Il Form 4 comunica la data di assegnazione dell'opzione il 03/05/2024 e che queste opzioni maturano mensilmente con pieno vesting un anno dopo l'assegnazione. La dichiarazione è firmata e datata 16/09/2025.
Alan W. Dunton, director de CorMedix Inc. (CRMD), reportó transacciones en el mismo día el 12/09/2025 en las acciones comunes de la compañía y opciones relacionadas. Ejerció una opción de compra con precio de ejercicio de $3.55 para adquirir 10,000 acciones, aumentando sus participaciones directas a 50,250 acciones, y vendió 10,000 acciones el mismo día en varias operaciones a un precio medio ponderado de $13.13, reduciendo sus participaciones directas a 40,250 acciones. El Formulario 4 revela la fecha de grant de la opción 05/03/2024 y que esas opciones se consolidan mensualmente con vesting completo al cabo de un año desde la concesión. La presentación está firmada y fechada el 16/09/2025.
Alan W. Dunton은 CorMedix Inc. (CRMD)의 이사로, 회사의 보통주와 관련 옵션에 대해 2025년 9월 12일 같은 날의 거래를 보고했습니다. 그는 행사 가격 $3.55의 주식매수선택권을 행사하여 10,000주를 취득했고 직접 보유 주식 수를 50,250주로 늘렸으며, 같은 날 여러 건의 거래에서 10,000주를 매도하여 가중 평균가 $13.13로 직접 보유를 40,250주로 감소시켰습니다. Form 4는 옵션 부여일 2024-03-05를 공시하고 그 옵션은 매월 vesting이 진행되어 부여 후 1년 차에 완전 vesting됩니다. 제출은 2025-09-16에 서명 및 날짜가 기재되어 있습니다.
Alan W. Dunton, administrateur chez CorMedix Inc. (CRMD), a déclaré des transactions effectuées le même jour le 12/09/2025 sur les actions ordinaires de la société et les options associées. Il a exercé une option d’achat avec un prix d’exercice de $3,55 pour acquérir 10 000 actions, portant ses avoirs directs à 50 250 actions, et a vendu 10 000 actions le même jour lors de plusieurs transactions à un prix moyen pondéré de $13,13, réduisant ses avoirs directs à 40 250 actions. Le Form 4 indique la date d’attribution de l’option 2024-03-05 et que ces options acquièrent des droits mois après mois avec une vesting complète un an après l’attribution. Le dépôt est signé et daté du 16/09/2025.
Alan W. Dunton, Direktor von CorMedix Inc. (CRMD), meldete am selben Tag den 12.09.2025 Transaktionen mit den Stammaktien des Unternehmens und verwandten Optionen. Er übte eine Optionsurkunde mit einem Ausübungspreis von $3.55 aus, um 10.000 Aktien zu erwerben, wodurch sich seine direkten Beteiligungen auf 50.250 Aktien erhöhten, und er verkaufte am selben Tag 10.000 Aktien in mehreren Trades zu einem gewichteten Durchschnittspreis von $13.13, wodurch sich seine direkten Beteiligungen auf 40.250 Aktien reduzierten. Das Formular 4 gibt das Optionsgewährungsdatum 2024-03-05 an und dass diese Optionen monatlich vesten, mit vollständigem Vesting ein Jahr nach der Gewährung. Die Einreichung ist unterschrieben und datiert 2025-09-16.
Alan W. Dunton، مدير في CorMedix Inc. (CRMD)، أبلغ عن معاملات في نفس اليوم بتاريخ 12/09/2025 على أسهم الشركة العادية وخيارات متعلقة. نفّذ خيار شراء بأسعار تنفيذ قدره $3.55 لشراء 10,000 سهم، مما رفع حصته المباشرة إلى 50,250 سهمًا، وبيع 10,000 سهم في اليوم نفسه في عدة صفقات بسعر متوسط مرجّح قدره $13.13، مما قلّل حصته المباشرة إلى 40,250 سهمًا. تُظهر النشرة Form 4 تاريخ منح الخيار 2024-03-05 وأن تلك الخيارات تتراكم شهريًا مع حدوث vesting كامل بعد عام من المنحة. تم التوقيع على الملف وتاريخه 2025-09-16.
Alan W. Dunton，CorMedix Inc.（CRMD）的董事，已在同日报告了于2025年9月12日的公司普通股及相关期权交易。他行使行权价为$3.55的股票期权，取得10,000 股，使其直接持股增加至50,250 股，并在同日以多笔交易以加权平均价$13.13出售10,000 股，将其直接持股降至40,250 股。Form 4披露的期权授予日期为2024-03-05，这些期权按月归属，授予后一年全部归属。 filing 的签署日期为2025-09-16。
- Option exercise disclosed with exercise price of $3.55
- Sale price disclosed as a weighted average of $13.13, with execution price range provided
- Vesting schedule disclosed for options granted 03/05/2024 with monthly vesting and full vesting at one year
- Direct beneficial ownership decreased from 50,250 to 40,250 shares after the reported sale
Insights
TL;DR: Director exercised options and sold the same number of shares, realizing proceeds while retaining significant ownership.
The reporting shows an option exercise at a $3.55 strike and an immediate sale at a weighted average of $13.13, indicating the director realized a material per-share spread of about $9.58 before costs and taxes. Direct beneficial ownership fell from 50,250 to 40,250 shares after the transactions, while 10,000 option shares remain exercisable, yielding total direct plus derivative exposure of 20,000 option-based shares and 40,250 common shares. For investors, these are routine Section 16 transactions reflecting liquidity-taking by an insider rather than a change in control or new strategic position.
TL;DR: Transactions are standard insider exercises and sales; disclosure is timely and properly documented.
The Form 4 lists the director status and provides required details: transaction codes, quantities, prices, option grant and vesting terms, and an explanatory footnote on trade prices. The reporting person checked the box indicating individual filing. The signature and date are present. From a governance perspective, documentation appears complete and transparent for these non-derivative and derivative changes, with no additional governance actions or disclosures evident in the filing.
Alan W. Dunton, direttore di CorMedix Inc. (CRMD), ha riportato operazioni nello stesso giorno il 12/09/2025 sulle azioni ordinarie della società e relative opzioni. Ha esercitato un'opzione con prezzo di esercizio di $3,55 per acquistare 10.000 azioni, aumentando le sue partecipazioni dirette a 50.250 azioni, e ha venduto 10.000 azioni nello stesso giorno in più operazioni a un prezzo medio ponderato di $13,13, riducendo le partecipazioni dirette a 40.250 azioni. Il Form 4 comunica la data di assegnazione dell'opzione il 03/05/2024 e che queste opzioni maturano mensilmente con pieno vesting un anno dopo l'assegnazione. La dichiarazione è firmata e datata 16/09/2025.
Alan W. Dunton, director de CorMedix Inc. (CRMD), reportó transacciones en el mismo día el 12/09/2025 en las acciones comunes de la compañía y opciones relacionadas. Ejerció una opción de compra con precio de ejercicio de $3.55 para adquirir 10,000 acciones, aumentando sus participaciones directas a 50,250 acciones, y vendió 10,000 acciones el mismo día en varias operaciones a un precio medio ponderado de $13.13, reduciendo sus participaciones directas a 40,250 acciones. El Formulario 4 revela la fecha de grant de la opción 05/03/2024 y que esas opciones se consolidan mensualmente con vesting completo al cabo de un año desde la concesión. La presentación está firmada y fechada el 16/09/2025.
Alan W. Dunton은 CorMedix Inc. (CRMD)의 이사로, 회사의 보통주와 관련 옵션에 대해 2025년 9월 12일 같은 날의 거래를 보고했습니다. 그는 행사 가격 $3.55의 주식매수선택권을 행사하여 10,000주를 취득했고 직접 보유 주식 수를 50,250주로 늘렸으며, 같은 날 여러 건의 거래에서 10,000주를 매도하여 가중 평균가 $13.13로 직접 보유를 40,250주로 감소시켰습니다. Form 4는 옵션 부여일 2024-03-05를 공시하고 그 옵션은 매월 vesting이 진행되어 부여 후 1년 차에 완전 vesting됩니다. 제출은 2025-09-16에 서명 및 날짜가 기재되어 있습니다.
Alan W. Dunton, administrateur chez CorMedix Inc. (CRMD), a déclaré des transactions effectuées le même jour le 12/09/2025 sur les actions ordinaires de la société et les options associées. Il a exercé une option d’achat avec un prix d’exercice de $3,55 pour acquérir 10 000 actions, portant ses avoirs directs à 50 250 actions, et a vendu 10 000 actions le même jour lors de plusieurs transactions à un prix moyen pondéré de $13,13, réduisant ses avoirs directs à 40 250 actions. Le Form 4 indique la date d’attribution de l’option 2024-03-05 et que ces options acquièrent des droits mois après mois avec une vesting complète un an après l’attribution. Le dépôt est signé et daté du 16/09/2025.
Alan W. Dunton, Direktor von CorMedix Inc. (CRMD), meldete am selben Tag den 12.09.2025 Transaktionen mit den Stammaktien des Unternehmens und verwandten Optionen. Er übte eine Optionsurkunde mit einem Ausübungspreis von $3.55 aus, um 10.000 Aktien zu erwerben, wodurch sich seine direkten Beteiligungen auf 50.250 Aktien erhöhten, und er verkaufte am selben Tag 10.000 Aktien in mehreren Trades zu einem gewichteten Durchschnittspreis von $13.13, wodurch sich seine direkten Beteiligungen auf 40.250 Aktien reduzierten. Das Formular 4 gibt das Optionsgewährungsdatum 2024-03-05 an und dass diese Optionen monatlich vesten, mit vollständigem Vesting ein Jahr nach der Gewährung. Die Einreichung ist unterschrieben und datiert 2025-09-16.
FAQ
What transactions did CRMD director Alan W. Dunton report on Form 4?
What price did Alan W. Dunton receive when selling CRMD shares?
How did these transactions affect Dunton's ownership in CRMD?
When were the options granted and what are the vesting terms?
When was the Form 4 signed and filed?
